Internal Medicine, Gastroenterology · Newport Beach, CA
NPI
1699972844
Since 2007
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
361 Hospital Rd, Ste 331
Newport Beach, CA, 92663
Phone (949) 645-8300
Groups this clinician bills Medicare through
Medicare paid, 2024
$120K
1,219 services
Medicare patients, 2024
475
Average age 75
Drug cost, 2024
$179K
2,046 prescriptions
Company payments, 2025
$477
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Homeira Mehrabian was code 99213 (office e&m - established), 445 times for 279 patients. In total Homeira Mehrabian billed 1,219 services in 26 codes, and Medicare paid $120K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-02-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 445 | 279 | $73.32 | $33K |
| 43239 Upper GI Endoscopy | Facility | 211 | 179 | $86.60 | $18K |
| 99203 Office E&M - New | Office | 151 | 151 | $87.21 | $13K |
| 45380 Lower GI Endoscopy - Other | Facility | 123 | 121 | $123.44 | $15K |
| 45385 Colonoscopy - Lesion Removal | Facility | 63 | 62 | $193.50 | $12K |
| 99214 Office E&M - Established | Office | 52 | 45 | $100.61 | $5,232 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 39 | 39 | $185.82 | $7,247 |
| 99204 Office E&M - New | Office | 29 | 29 | $128.38 | $3,723 |
| 99232 Hospital E&M - Subsequent | Facility | 24 | 19 | $64.03 | $1,537 |
| 45378 Lower GI Endoscopy - Other | Facility | 24 | 24 | $136.48 | $3,275 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 11 | 11 | $134.88 | $1,484 |
By year: 2022 $96K for 922 services; 2023 $119K for 1,196 services; 2024 $120K for 1,219 services.
Medicare prescription drug claims, 2024
In 2024, the drug Homeira Mehrabian prescribed most often to Medicare patients was Pantoprazole Sodium, with 853 prescriptions and refills. In total Homeira Mehrabian wrote 2,046 Medicare prescriptions that cost $179K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 853 | 1,600 | 245 | $9,948 |
| Famotidine Generic | 408 | 950 | 132 | $4,998 |
| Sucralfate Generic | 213 | 362 | 78 | $4,176 |
| Ondansetron Hcl Generic | 196 | 196 | 180 | $497 |
| Omeprazole Generic | 49 | 139 | 16 | $698 |
| Dicyclomine Hcl Generic | 49 | 103 | 19 | $1,864 |
| Linzess Linaclotide | 44 | 56 | 11 | $28K |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 37 | 37 | 29 | $2,376 |
| Sutab Sod Sulf/Pot Chloride/Mag Sulf | 31 | 31 | 30 | $6,581 |
| Prevalite Cholestyramine | 23 | 37 | Under 11 | $4,529 |
| Cholestyramine Light Cholestyramine | 20 | 28 | Under 11 | $3,009 |
| Esomeprazole Magnesium Generic | 16 | 40 | Under 11 | $2,068 |
| Dexlansoprazole Dr Dexlansoprazole | 12 | 12 | Under 11 | $1,538 |
| Lubiprostone Generic | 11 | 21 | Under 11 | $2,125 |
| Rabeprazole Sodium Generic | 11 | 11 | Under 11 | $345 |
Brand drugs: 145 claims; generic drugs: 1,901 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Homeira Mehrabian $477 ($477 in general payments such as food, travel and fees) from 9 companies. The largest payer was Salix Pharmaceuticals, a division of Bausch Health US, LLC with $113.
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 5 | $113 |
| Genzyme Corporation SNY | 3 | $113 |
| Cook Medical LLC | 1 | $106 |
| Madrigal Pharmaceuticals MDGL | 1 | $33.35 |
| Abbvie Inc. ABBV | 1 | $24.72 |
| Novo Nordisk Inc NVO | 1 | $24.65 |
| Phathom Pharmaceuticals, Inc. PHAT | 1 | $23.62 |
| Janssen Biotech, Inc. JNJ | 1 | $22.24 |
| Exact Sciences Corporation EXAS | 1 | $17.15 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.